KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.

Myung J Ahn, Hye R Kim, James C H Yang, Ji-Yu Han, Jacky Yu-Chung Li, Maximilian J Hochmair, Gee-Chen Chang, Angelo Delmonte, Ki H Lee, Rosario G Campelo, Cesare Gridelli, Alexander I Spira, Raffaele Califano, Frank Griesinger, Sharmistha Ghosh, Enriqueta Felip, Dong-Wan Kim, Yuyin Liu, Pingkuan Zhang, Sanjay Popat, D Ross Camidge

Clin Lung Cancer 23(8) 720-730

PMID36038416
PMCID-
DOI10.1016/j.cllc.2022.07.008
发表日期2022-08-29
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

BACKGROUND: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial. PATIENTS AND METHODS: This was a subgroup analysis from the phase III ALTA-1L trial of brigatinib vs. crizotinib in ALK inhibitor-naive ALK+ NSCLC. The primary endpoint was progression-free survival (PFS) as assessed by blinded independent review committee (BIRC). Secondary endpoints included confirmed objective response rate (ORR) and overall survival (OS) in the overall population and BIRC-assessed intracranial ORR and PFS in patients with brain metastases. RESULTS: Of the 275 randomized patients, 108 were Asian. Brigatinib showed consistent superiority in BIRC-assessed PFS vs. crizotinib in Asian (hazard ratio [HR]: 0.35 [95% CI: 0.20-0.59]; log-rank P = .0001; median 24.0 vs. 11.1 months) and non-Asian (HR: 0.56 [95% CI: 0.38-0.84]; log-rank P = .0041; median 24.7 vs. 9.4 months) patients. Results were consistent with investigator-assessed PFS and BIRC-assessed intracranial PFS. Brigatinib was well tolerated. Toxicity profiles and dose modification rates were similar between Asian and non-Asian patients. CONCLUSION: Efficacy with brigatinib was consistently better than with crizotinib in Asian and non-Asian patients with locally advanced or metastatic ALK inhibitor-naive ALK-+ NSCLC. There were no clinically notable differences in overall safety in Asian vs. non-Asian patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。